NRF2 signaling cascade in amyotrophic lateral sclerosis: bridging the gap between promise and reality - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Neural Regeneration Research Année : 2024

NRF2 signaling cascade in amyotrophic lateral sclerosis: bridging the gap between promise and reality

Résumé

Abstract Amyotrophic lateral sclerosis is a very disabling disease due to the degeneration of motor neurons. Symptoms include muscle weakness and atrophy, spasticity, and progressive paralysis. Currently, there is no treatment to reverse damage to motor neurons and cure amyotrophic lateral sclerosis. The only two treatments actually approved, riluzole and edaravone, have shown mitigated beneficial effects. The difficulty to find a cure lies in the complexity and multifaceted pattern of amyotrophic lateral sclerosis pathogenesis. Among mechanisms, abnormal RNA metabolism, nucleocytoplasmic transport defects, accumulation of unfolded protein, and mitochondrial dysfunction would in fine induce oxidative damage and vice versa . A potent therapeutic strategy will be to find molecules that break this vicious circle. Sharpening the nuclear factor erythroid-2 related factor 2 signaling may fulfill this objective since nuclear factor erythroid-2 related factor 2 has a multitarget profile controlling antioxidant defense, mitochondrial functioning, and inflammation. We here discuss the interest of developing nuclear factor erythroid-2 related factor 2-based therapy in regard to the pathophysiological mechanisms and we provide a general overview of the attempted clinical assays in amyotrophic lateral sclerosis.

Dates et versions

hal-04436982 , version 1 (04-02-2024)

Identifiants

Citer

Pauline Tarot, Christelle Lasbleiz, Jean-Charles Liévens. NRF2 signaling cascade in amyotrophic lateral sclerosis: bridging the gap between promise and reality. Neural Regeneration Research, 2024, 19 (5), pp.1006-1012. ⟨10.4103/1673-5374.385283⟩. ⟨hal-04436982⟩

Collections

EPHE MMDN PSL BS
22 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More